Antibody Mediated Rejection is not Associated with Worse Survival in Adherent Heart Transplant Patients in the Contemporary Era

Background: C4d immunostaining of surveillance endomyocardial biopsies (EMB) and testing for donor specific antibodies (DSA) are routinely performed in the first year of heart transplantation (HTx) in adult patients. C4d and DSA positivity have not been evaluated together with respect to clinical outcomes in the contemporary era (2010–current). Methods: This was a single center, retrospective study of consecutive EMBs performed between November 2010 and April 2023. The primary objective was to determine whether history of C4d and/or DSA positivity could predict death, cardiac death, or retransplant. Secondary analyses included cardiac allograft dysfunction and cardiac allograft vasculopathy. Cox proportional hazards models were used for single predictor and multipredictor analyses. Results: A total of 6,033 EMBs from 519 HTx patients were reviewed for the study. There was no significant difference (p = 0.110) in all-cause mortality or cardiac retransplant between four groups: C4d+/DSA+, C4d+/DSA−, C4d−/DSA+, and C4d−/DSA−. The risk for cardiac mortality or retransplant was significantly higher in C4d+/DSA+ versus C4d−/DSA− patients (HR = 4.73; pc = 0.042) but not significantly different in C4d+/DSA− versus C4d−/DSA− patients (pc = 1.000). Similarly, the risk for cardiac allograft dysfunction was significantly higher in C4d+/DSA+ versus C4d−/DSA− patients (HR 3.26; pc = 0.001) but not significantly different in C4d+/DSA− versus C4d−/DSA− patients (pc = 1.000). Accounting for nonadherence, C4d/DSA status continued to predict cardiac allograft dysfunction but no longer predicted cardiac death or retransplant. Conclusions: Medically adherent C4d+/DSA+ HTx patients show significantly greater risk for cardiac allograft dysfunction but not cardiac mortality or retransplant. In contrast, C4d+/DSA− patients represent a new immunopathologic group with a clinical course similar to that of HTx patients without antibody mediated rejection.


Conclusions:
Adherent C4d+/DSA+ HTx patients show significantly increased risk for cardiac allograft dysfunction but not cardiac mortality or retransplant.In contrast, C4d+/DSA-patients represent a new immunopathologic group with a clinical course similar to normal HTx patients. .

Introduction
The pathologic criteria for antibody mediated rejection (AMR) in heart transplant (HTx) patients has made significant progress since its early description in literature, [1][2][3] and evolved to the current application of immunopathologic criteria that includes C4d, C3d, and/or CD68 immunostaining, defined by the International Society for Heart and Lung Transplantation (ISHLT) Working Formulation in 2013. 4,58][9][10][11][12] The immunopathologic criteria from the ISHLT created five different pAMR grades, including two subtypes of pAMR1 -pAMR1(I + ) and pAMR1(H + ).However, the clinical significance of the different immunopathologic grades are not fully understood. 5,13,14Furthermore, the clinical significance of C4d positivity itself remains an area of active research, especially since the 2013 ISHLT Working Formulation and 2015 AHA Scientific Statement. 4,5,7,9,10,12,14e association of DSA positivity and poor clinical outcomes have also been well documented. 8,15- 17 9][20] Thus, this study aimed to examine the role of both C4d and DSA positivity in adult HTx patients related to clinical outcomes, including all-cause death, cardiac death or retransplant. .

Materials and Methods: Data Sharing
The data that support the findings of this study are available upon request.

Study Design
Consecutive heart transplant (HTx) patients who were 18 years of age or older and underwent right ventricular endomyocardial biopsy (EMB) between November 2010 to April 2023 were retrospectively reviewed.At the University of California, San Diego Health (UC San Diego Health), the typical EMB surveillance protocol includes EMBs performed biweekly for the first 3 months and monthly afterwards during the first year post-HTx.After 1 year post-HTx, EMBs were typically performed as for cause EMBs.UC San Diego protocol includes C4d immunofluorescence at 2 and 4 weeks, and at 3, 6 and 12 months during surveillance EMBs in addition to for cause EMB indication as per the International Society for Heart and Lung Transplantation (ISHLT). 4,5DSA testing is also performed at the same time intervals for surveillance indication and whenever there is clinical concern for AMR.The authors (VC, AC, PB, JC) collected patient data and clinical outcomes from the electronic medical record.Approval for this study was provided by the UC San Diego Health Office of IRB Administration (IRB #805675).This study adheres to the principles of the Declaration of Helsinki formulated by the World Medical Association and the US Federal Policy for the Protection of Human Subjects.

Comparison Groups
HTx patients with C4d and DSA testing information were included for this study.Additionally, since the specific goal of this study was to evaluate clinical outcomes associated with C4d and DSA positivity, patients diagnosed with pathological antibody mediated rejection (pAMR) without positive C4d immunofluorescence (i.e., by histology or CD68 positivity) 4 were also excluded from the study.C3d immunofluorescence was not used at UC San Diego during the study period.

Pathological Tissue Exams and DSA testing
The results of pathological tissue exams were collected for each EMB.C4d immunofluorescence was performed starting November 2010 at UC San Diego Health.C4d positivity was defined as multifocal/diffuse weak or strong staining as per the ISHLT. 4Acute cellular rejection (ACR) grading was performed per ISHLT guidelines 21 and grades 2R and 3R were defined as clinically significant ACR.pAMR grading scheme for AMR 4 was performed and grades > pAMR 1 were considered positive for this study.Donor specific antibody (DSA) testing was performed using FlexMap 3D (Luminex, Austin, Tx) instruments with normalized mean fluorescence intensity values of 3,000 used to identify "positive" antibodies. 22For this study, concurrent DSA positivity was defined by a positive DSA result within a month of the C4d result.

Clinical Outcomes and Variables
All patients were followed for all-cause death.Cause of death was adjudicated by two experienced HTx cardiologists (NW and PJK).When there was a disagreement, a third cardiologist (YT) made the final determination.Other clinical outcomes included: ISHLT cardiac allograft vasculopathy (CAV) grade 2 or greater 23 , cardiac retransplant, cardiac allograft dysfunction (echocardiogram demonstrating left ventricular ejection fraction < 50% and excluding primary graft dysfunction 24 ), and future episodes of AMR and/or ACR.For this study, if cardiac allograft dysfunction and/or CAV were noted within 6 months of a C4d result and no other recent studies identified, then cardiac allograft dysfunction and/or CAV would be recorded as concurrent with the C4d result.
Additional clinical variables recorded included: recipient age, sex, race/ethnicity, recipient body mass index (BMI), recipient multiorgan status, recipient blood type, United Network for Organ Sharing calculated panel of reactive antibodies, durable mechanical circulatory support (MCS) at the time of HTx, etiology of cardiomyopathy pre-HTx, donor age, donor sex, donor BMI, donation after cardiac death donor status, predicted heart mass (PHM) difference, extracorporeal membrane oxygenation (ECMO) pre-and post-transplant, percutaneous mechanical circulatory support (pMCS) pre-and post-transplant, cold ischemic time, use of induction therapy, cytomegalovirus status, de novo DSA status, DSA class I and II serologic subtypes, first pAMR grade at time of C4d positivity, highest pAMR grade, total number of separate AMR episodes, immunomodulatory treatment for c4d positivity, history of ACR, ACR grade at time of C4d positivity, indication of EMB at the time of C4d positivity, and intracardiac pressure measurements and cardiac index by Fick calculation at the time of C4d positivity.Immunomodulatory treatment for AMR refers to a significant change in a subject's immunomodulatory regimen including: initiation or increase in corticosteroids to a prednisone equivalent of 40 mg/day or higher, intravenous immune globulin, plasmapheresis, rituximab, thymoglobulin, and/or bortezomib use.

Medical Nonadherence
Documentation by any clinical team member of medical nonadherence after HTx was recorded as nonadherence by the authors (VC, AC, PB, JC).Medical adherence was considered broadly post-HTx, based on the clinical team's assessment and charting, and not exclusive to adherence to immunosuppressive medications.

Statistical Analysis
. Continuous variables were expressed as mean + standard deviation (SD) for normally distributed variables or median and interquartile range (IQR) for non-normally distributed variables and compared with the use of the Student's t-test or Wilcoxon rank-sum test, respectively.The Kruskal-Wallis test was used for multiple group comparisons of continuous data.Categorical variables were expressed as counts and percentages and compared between groups using either the Pearson's chi-square or Fisher's exact test whenever any observed counts were < 5.If the null hypothesis was rejected, pairwise group comparisons using the Bonferroni-Holm procedure were subsequently performed.The agreement rate between the two adjudicators for clinical outcomes was performed using Cohen's kappa statistics.
The association of C4d/DSA groups with time to event outcomes (all cause death, cardiac death or retransplant, cardiac allograft dysfunction, CAV, C4d positivity, DSA positivity, C4d+/DSA+ positivity, and future treated ACR) was evaluated using single predictor and multipredictor Cox proportional hazards models.The multipredictor model adjusted for potential confounders (recipient, donor, and appropriate transplant characteristics) via backward model selection with p-value < 0.15 threshold for inclusion.Additional exploratory analyses investigated factors associated with time to event outcomes using Cox models applying a similar backwards model selection procedure, except for time to CAV analysis where a forwards model selection procedure was used due to a relatively low number of events compared to the number of predictors evaluated.Medical nonadherence was only evaluated as a potential predictor in exploratory analyses.Cause-specific hazard models were used to address etiologic questions.The Fine-Gray subdistribution hazard models were also performed to evaluate the effect of covariates on competing risks.

Patient Demographics
A total of 560 HTx patients were identified and deemed potentially eligible for the study (Figure 1).Of these, 31 patients were excluded for not having documentation of C4d immunofluorescence.Because our study was specific to C4d and DSA positivity, 10 patients were also excluded for the diagnosis of pAMR using CD68 + immunostaining or histology criteria 4 without C4d positivity.
Baseline characteristics of the study population are depicted in Table 1.Patients were typically male (81%) and non-hispanic white (41%) with a mean age of 54 ± 14 years at the time of HTx.
There were 1,855.1 person-years in this study from HTx to end of follow-up.

Association of C4d and DSA status with all cause death, cardiac death, or retransplant
Of the 519 patients, 58 (11.2%) died or underwent cardiac retransplant during the follow-up period (Supplementary Table S1).Of the deaths, 5 (9.3%) were due to cancer, 16 (29.6%)were due to cardiac causes, 22 (40.7%) were due to infection, 7 (13.0%)were due to other causes, and 4 (7.4%) were due to unknown causes.Initial adjudication of cause of death was in agreement 88.1% of the time with a Cohen's kappa of 0.84 (0.72, 0.96; p < 0.001).
There was no significant difference in all-cause mortality or cardiac retransplant between the four groups (Figure 3; adjusted p-value = 0.110).However, there was a significantly increased risk in cardiac mortality or retransplant in C4d+/DSA+ compared to C4d-/DSA-patients (Figure 4; hazard ratio [HR] = 4.73; 95% confidence interval [CI] 1.57-14.27;pc = 0.042).There was no significant difference in cardiac mortality or transplant in C4d+/DSA-compared to C4d-/DSApatients (pc = 1.000).The Fine-Gray subdistribution hazard model also demonstrated consistent findings with the cause-specific hazard model (p = 0.001).Of note, we observed all cardiac deaths of patients with C4d positivity occurred in-hospital.
For prediction of DSA positivity, we found recipient age, medical nonadherence, and allosensitization status pre-HTx by panel of reactive antibodies (PRA) to be significant independent risk factors (Supplementary Table S4).For prediction of C4d positivity, we found class 1 and 2 antibodies, medical nonadherence, and female recipient sex to be significant independent predictors (Supplementary Table S5).
For cardiac allograft dysfunction, we found medical nonadherence, C4d/DSA status, PHM difference, HTx indication, and ECMO pre-and post-HTx to be significant independent predictors (Table 3 and Supplementary Table S6).Post hoc analysis of C4d/DSA status demonstrated significantly increased risk for cardiac allograft dysfunction in C4d+/DSA+ compared to C4d-/DSA-patients (HR 3.26; 95% CI, 1.75-6.08;pc = 0.001).There was no significant difference in risk for cardiac allograft dysfunction in C4d+/DSA-(pc = 1.000) and C4d-/DSA+ (pc = 1.000) compared to C4d-/DSA-patients.We did not find severity of the ACR grade with concurrent C4d positivity to correlate with cardiac allograft dysfunction (p = 0.227).We also did not find the severity of the pAMR grade with concurrent C4d positivity (p = 0.313) nor the number of AMR episodes (p = 0.742) to correlate with cardiac allograft dysfunction.
For future CAV, given the relatively low number of events (n = 30), we performed a post hoc pairwise comparisons of the primary variable of interest, C4d/DSA patient groups, and adjusted for identified confounders (Supplementary Table S7).We observed a trend for predicting CAV in C4d+/DSA+ compared to C4d-/DSA-patients (HR 3.52; 95% CI, 1.21-10.24;pc = 0.063).The C4d+/DSA-group (pc = 0.527) did not show a significant difference compared to C4d-/DSApatients for predicting CAV.Of note, 360 (69.4%) patients from the study cohort, 54 (83.1%) of all C4d+ patients, 19 (82.6%) of C4d+ patients with cardiac allograft dysfunction, and 12 (85.7%) of the nonadherent C4d+ patients with cardiac allograft dysfunction were evaluated for CAV by coronary angiography.Of the 7 nonadherent C4d+/DSA+ patients with cardiac mortality or retransplant, there was only 1 patient where a coronary angiogram result was not performed within 6 months prior to the cardiac death.

Discussion
In this retrospective cohort of 544 HTx patients with greater than 2,000 patient-years of follow-up, the following key findings were observed.First, C4d+/DSA+ patients demonstrated significantly increased cardiac morbidity, mortality, or retransplant when compared to C4d+/DSA-patients.
AMR is typically diagnosed by pathologic criteria, set forth in the last Working Formulation by the ISHLT, which has greatly improved the sensitivity for the diagnosis of pAMR. 4,30However, we show that the new immunopathologic criteria and the recommendation to routinely perform DSA testing 31 in the first year after HTx contributed to the classification of a novel C4d+/DSA-group that has not been well described in the contemporary era (2010 to current). 8,12,20In the current study, we find that C4d+/DSA-patients are a clinically distinct group compared to C4d+/DSA+ patients.C4d+/DSA+ patients demonstrated significantly increased cardiac allograft dysfunction .and cardiac death or retransplant compared to C4d+/DSA-patients.After adjusting for medical nonadherence, C4d+/DSA+ patients continued to demonstrate a significantly increased risk in cardiac allograft dysfunction and a trend towards increased CAV prevalence.Thus, we show that C4d+/DSA+ patients are at higher risk for future clinical events compared to C4d+/DSA-patients.
Recently, RNA-sequencing of EMBs demonstrated marked transcriptomic differences between DSA+ and DSA-groups in AMR patients, with significant upregulation of genes related to immunity in DSA+ AMR patients. 14Our study also supports the finding that C4d+/DSA-patients represent a new immunopathologic group, with a clinical course not significantly different compared to the C4d-/DSA-group.
The onset of C4d positivity occurred significantly earlier in the C4d+/DSA-group, at 1 month post-HTx, compared to 9 months post-HTx in the C4d+/DSA+ group.2][43] Our study findings support the hypothesis that the mechanism for complement activation and deposition in C4d+/DSA-patients is different from C4d+/DSA+ patients and possibly the result of reperfusion injury.
We also found the clinical differences at time of presentation to be significantly different for the C4d+/DSA+ compared to C4d+/DSA-patients.The majority (98%) of C4d+/DSA+ patients demonstrated DSA positivity either concurrent with or within a year of C4d positivity.Additionally, C4d+/DSA+ patients presented with significantly increased intracardiac filling pressures 7,44 at the time of C4d positivity compared to C4d+/DSA-patients.Consequently, the management of C4d+/DSA+ patients did not appear to be affected necessarily by the DSA result at the time of C4d positivity.The majority (80%) of C4d+/DSA+ patients received some type of immunomodulatory treatment in addition to their baseline immunosuppression regimen.However, the treatment regimens varied widely with intravenous immunoglobulins and plasmapheresis being more frequently used compared to others. 5,7novel finding from our study is that medical nonadherence is significantly correlated to C4d+/DSA+ status and ultimately, cardiac death or retransplant.We found medical nonadherence to be significantly associated with DSA positivity, C4d positivity, cardiac allograft dysfunction, and cardiac death or retransplant.However, we did not find medical nonadherence to be significantly associated with CAV.We believe this finding does not contradict prior literature describing correlation observed between AMR and CAV.7,9,20,37,[44][45][46][47][48][49] Instead, our study results complement current literature and show that there is more than one mode of cardiac death in the C4d+/DSA+ group and is associated with adherence status.Thus, we hypothesize that medical nonadherence contributes to DSA production, C4d deposition, subsequent cardiac allograft dysfunction, and resultant cardiac death or retransplant.As a related observation, we find in our study that while adherent C4d+/DSA+ patients are at an increased risk for cardiac allograft dysfunction, they do not demonstrate the increased risk for cardiac death or retransplant as do nonadherent C4d+/DSA+ patients.However, the mechanism(s) for why nonadherent C4d+/DSA+ patients are at an increased risk of cardiac death or retransplant is unclear.We did not find a correlation with cardiac allograft dysfunction and severity of pAMR grading, number of AMR episodes, nor mixed acute rejection.Further study of cardiac allograft dysfunction and prediction for cardiac death or retransplant will be important to better understand this relationship.
In our study cohort, class 2 DSA positivity was a relatively common occurrence (21%), 8,11,19,20,50- 52 while HTx patients with both class 1 and 2 DSA positivity was much less frequent (6%). 53rthermore, we found that patients who were both class 1 and 2 DSA positive were at a significantly increased risk for being in the C4d+/DSA+ rather than C4d-/DSA+ group.This .observation contributes to existing literature 8,17,20,54,55 and is important for HTx patients that become DSA positive as we did not find the majority of these patients (i.e., C4d-/DSA+ group) to be at increased risk for all cause death, cardiac death or retransplant, CAV, and cardiac allograft dysfunction compared to C4d-/DSA-patients.Further study of class 1 and 2 DSAs, including at a higher molecular resolution 22,56 , may provide additional insights of the risks specific DSAs pose to HTx patients.
Due to significant variation in treatment and as most (80%) C4d+/DSA+ patients received some form of immunomodulatory treatment, we could not make any confident conclusions on the effect of treatment on clinical outcomes within the C4d+/DSA+ group.Randomized control trials to better identify C4d+/DSA+ patients that need treatment and what type of immunomodulatory treatment will be important going forward. 7,57,58nally, our study adds to the evolving literature of "biopsy-negative rejection" after HTx. 59We show cardiac allograft dysfunction occurs most frequently in the C4d+/DSA+ group but also occurs in other C4d/DSA groups without an identified cause.With continued research in non-HLA antibodies 60 and immunopathology, 13,14,61 particularly with RNA-sequencing, we believe we will see further classification of immunophenotypes and greater understanding biologically and clinically of these patients.

Limitations
This study should be interpreted within the context of several important limitations.First, this was a retrospective study from a single center and may not necessarily represent the experience of other centers with different patient demographics and variations in post-HTx management.
Second, the number of cardiac deaths or retransplants were low for all groups.However, we still .found the time to cardiac death or retransplant to be significantly different in C4d+/DSA+ compared to C4d-/DSA-patients but this was no longer significant after adjusting for medical nonadherence.Third, while our study represents a sizable cohort relative to other single center studies, [7][8][9]18,62 the C4d+/DSA-group represented a minority of total HTx patients. Thus,our study remains underpowered to detect smaller differences and larger, multicenter studies should be performed to confirm our findings.Fourth, we chose C4d immunofluorescence as a prognostic biomarker 12 instead of pAMR grading because its simplicity and potential concerns of "overcalls" of pAMR2 without C4d positivity.63 However, we recognize there is ongoing research of pAMR1(H + ) and more study in this area is needed.13,14       There was a significantly increased cardiac mortality or retransplant in C4d+/DSA+ compared to C4d-/DSApatients (pc = 0.042).However, there was no significant difference in cardiac mortality or retransplant in C4d+/DSA-compared to C4d-/DSA-patients (pc = 1.000).DSA, donor-specific antibodies.

Conclusions
C4d+/DSA+ group showed a significantly increased median time to C4d positivity compared to the C4d+/DSA-group (Supplementary Figure S1; 33.6 vs 3.6 weeks; p = 0.004).For the C4d+/DSA+ group, 36 (90.0%) patients demonstrated positive DSA concurrent with C4d positivity and the median time from DSA to C4d positivity was 4.5 days (IQR, 0.0-41.0days) for these patients.Of the 4 patients that did not demonstrate positive DSA concurrent with C4d positivity, 3 patients demonstrated positive DSA within 1 year of C4d positivity while 1 patient demonstrated positive DSA after 1 year.Despite an initially negative DSA, three of the four C4d+/DSA+ patients were still treated for AMR.
C4d immunofluorescence and DSA positivity are simple yet useful biomarkers in the contemporary era for HTx patients with AMR.Medically adherent C4d+/DSA+ patients show increased cardiac allograft dysfunction but not increased cardiac death or retransplant compared to normal HTx patients.C4d+/DSA-patients represent a new immunopathologic group with a clinical course similar to that of normal HTx patients..

Figure 3 .
Figure 3. Kaplan-Meier Curves for Overall Survival by C4d/DSA status.There was no significant difference in overall survival between groups by C4d/DSA status (adjusted p-value = 0.143).DSA, donor-specific antibodies.

Table 2 .
Multipredictor model for cardiac mortality or retransplant as the outcome.AMR, antibody mediated rejection; CI, confidence interval; DCD, donation after cardiac death; HR, hazard ratio; pMCS, percutaneous mechanical circulatory support.

Table S7 .
Pairwise comparisons of C4d/DSA groups for cardiac allograft vasculopathy as the outcome.Pairwise comparisons were adjusted for the identified confounders of donor age, cold ischemic time, and predicted heart mass difference by the forward model selection procedure.CI, confidence interval; DSA, donor-specific antibodies; HR, hazard ratio.# , reference is C4d-/DSA-group.